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mpact of Initiating Carvedilol Before Angiotensin-
onverting Enzyme Inhibitor Therapy on
ardiac Function in Newly Diagnosed Heart Failure
aren Sliwa, MD, PHD,* Gavin R. Norton, MD, PHD,‡ Ngalulawa Kone, MD,† Geoffrey Candy, PHD,*
ohn Kachope, MD,* Angela J. Woodiwiss, PHD,‡ Carlos Libhaber, MD,* Pinhas Sareli, MD,*
afique Essop, MD*
ohannesburg, South Africa
OBJECTIVES The purpose of this research was to evaluate the therapeutic value of initiating a beta-blocker
before an angiotensin-converting enzyme inhibitor (ACEI) in the treatment of heart failure.
BACKGROUND Although ACEI and carvedilol produce benefits in heart failure, whether the order of
initiation of therapy determines the impact on left ventricular (LV) function and New York
Heart Association functional class (NYHA FC) has not been determined.
METHODS A single-center, prospective, randomized, open-label study was performed. We evaluated
whether initiation of therapy with carvedilol either before (n  38) or after (n  40)
perindopril therapy in newly diagnosed patients in NYHA FC II to III heart failure with
idiopathic dilated cardiomyopathy, with the addition of the alternative agent after six months,
determined subsequent changes in NYHA FC and LV function (echocardiography and
radionuclide ventriculography). Study drugs were titrated to maximum tolerable doses.
RESULTS There were no differences in baseline characteristics between the study groups. After 12
months 11 patients died (6 in the group where the ACEI was initiated). At 12 months the
group receiving carvedilol as initial therapy achieved a higher tolerable dose of carvedilol (43
 17 mg vs. 33  18 mg, p  0.03); a lower dose of furosemide (p  0.05); and better
improvements in symptoms (NYHA FC, p  0.002), LV ejection fraction (radionuclide: 15
 16% vs. 6  13%, p  0.05; echocardiographic, p  0.01), and plasma N-terminal
pro-brain natriuretic peptide concentrations (p  0.02).
CONCLUSIONS As opposed to the conventional sequence of drug use in the treatment of heart failure,
initiation of therapy with carvedilol before an ACEI results in higher tolerable doses of
carvedilol and better improvements in FC and LV function. (J Am Coll Cardiol 2004;44:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.05.0871825–30) © 2004 by the American College of Cardiology Foundation
b
o
i
c
b
r
h
r
w
m
p
s
i
r
a
w
A
e
A
b
Hongestive cardiac failure is a complex clinical syndrome,
he progression of which is thought to be determined, in
art, by activation of neurohumoral (particularly renin-
ngiotensin and adrenergic) systems (1). Neurohumoral
ubstances are capable of altering the function and structure
f the heart via both direct effects on cardiomyocyte biology
See page 1831
nd the extracellular matrix, the consequence of which is
educed ventricular function and enhanced loading condi-
ions (2–4). Inhibition of the renin-angiotensin and adren-
rgic systems has subsequently become the mainstay of
ontemporary pharmacologic management of patients with
hronic heart failure (2,3).
From the *Department of Cardiology, Chris-Hani-Baragwanath Hospital,
ohannesburg, South Africa; †Department of Chemical Pathology, Chris-
ani-Baragwanath Hospital, Johannesburg, South Africa; and the ‡Department of
hysiology, University of the Witwatersrand, Johannesburg, South Africa. Supported
y educational grants from Roche Pharmaceuticals and Servier Pharmaceuticals,
outh Africa.c
Manuscript received March 7, 2004; revised manuscript received May 13, 2004,
ccepted May 18, 2004.In the treatment of heart failure with pump dysfunction,
eta-blocking agents are conventionally administered once
ptimal therapy with angiotensin-converting enzyme inhib-
tors (ACEI) is achieved. This approach is employed be-
ause clinical studies showing therapeutic benefits of beta-
lockers (BBs) were originally conducted in patients
eceiving ACEI (5–7). Importantly, however, in chronic
eart failure, sympathetic activation precedes that of the
enin-angiotensin system (8). Moreover, the mechanisms by
hich beta-adrenergic receptor activation mediates detri-
ental effects in heart failure is thought to involve cellular
athways that are modulated by both the renin-angiotensin
ystem (9) as well as by beta-adrenergic receptor-induced
ntracellular signaling pathways that are independent of the
enin-angiotensin system (10). Therefore, the question
rises as to whether more substantial benefits are realized
hen maximal doses of BBs are achieved before initiating
CEI therapy. Consequently, in the present study, we
valuated whether the order of initiation of a BB relative to
CEI therapy determines the impact of neurohumoral
lockade on left ventricular (LV) function, New York
eart Association functional class (NYHA FC), and bio-hemical indexes of heart failure (plasma N-terminal pro-
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11]) in newly diagnosed patients with heart failure due to
diopathic dilated cardiomyopathy.
ETHODS
tudy design and patient groups. The Committee for Re-
earch in Human Subjects of the University of Witwatersrand
pproved the protocol. This was a single-center, prospective,
andomized, open-label study conducted in 78 consecutive
atients with newly diagnosed idiopathic dilated cardiomyop-
thy in NYHA FC II to III heart failure. The study was
nitiated, conducted, and analyzed by the investigators. Inclu-
ion criteria: 1) age18 and70 years; 2) NYHA FC II or III
ongestive heart failure of unknown etiology; 3) left ventricular
jection fraction (LVEF)40% as determined by radionuclide
entriculography; 4) sinus rhythm. Exclusion criteria: 1)
hronic obstructive pulmonary disease; 2) significant valvular
eart disease; 3) history or evidence of ischemic heart disease;
) systolic blood pressure160 mm Hg and/or diastolic blood
ressure 95 mm Hg.
After initial presentation, and following a diagnosis by
linical examination and echocardiography (screening
isit), all patients received treatment with digoxin and
iuretics for seven days. Patients were then randomized
o receive either the ACEI perindopril (ACEI-first
roup, n  40) or the BB carvedilol (BB-first group, n 
8) in addition to diuretics and digoxin for a further six
onths. After six months, carvedilol was added to the
herapeutic regimen in those receiving the ACEI, and
erindopril was added to the therapeutic regimen in those
eceiving carvedilol. Both study drugs were titrated to
aximum tolerable doses, where systolic blood pressure
as maintained at 85 mm Hg, no dizziness was
eported, and orthostatic hypotension did not occur. The
arget dose of perindopril was 8 mg daily and carvedilol
5 mg twice a day. During the course of the study, the
ose of furosemide was titrated to lower values according
o the presence or absence of clinical features of conges-
ion and edema. Monthly visits were scheduled for
linical assessment and evaluation of patient’s adherence
o therapeutic agents. Clinical examinations, echocardio-
raphic assessments, radionuclide studies, and plasma
T-pro-BNP concentrations were determined at base-
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
BB  beta-blocker
LV  left ventricle/ventricular
LVEDD  left ventricular end-diastolic diameter
LVEF  left ventricular ejection fraction
LVESD  left ventricular end-systolic diameter
NT-pro-BNP  N-terminal pro-brain natriuretic peptide
NYHA FC  New York Heart Association functional
classine, and then repeated at 6 and at 12 months after tandomization. The primary end point was LVEF deter-
ined by using radionuclide ventriculography. To show a
0-point difference in radionuclide LVEF between
roups with 80% power after 12 months of therapy
equired a sample size of 23 patients in each group.
YHA FC, echocardiography, and radionuclide studies.
physician who was unaware of the treatment assigned
ssessed the NYHA FC of the patients during the baseline
nd follow-up visits. The same physician evaluated all
atients.
A multiple-gated equilibrium cardiac blood pool scinti-
raphic technique was used to measure LVEF (Elscint Apex
09, ELSCINT, Chicago, Illinois), and calculations of LV
erformance were made as previously described (12). Two-
imensional targeted M-mode echocardiography with
oppler color flow mapping was performed using a Hewlett
ackard Sonos 5500 (Philips, Washington, DC) echocar-
iograph. All studies were performed and interpreted by the
ame operator and recorded on videotape. Left ventricular
imensions were measured according to the American
ociety of Echocardiography guidelines (13). Diastolic mi-
ral flow was assessed by pulsed-wave Doppler echocardi-
graphy from the apical four-chamber view. The E-wave
eceleration time was measured as the interval between the
eak early diastolic velocity and the point at which the
teepest deceleration slope was extrapolated to the zero line.
he investigators that performed and interpreted the radio-
uclide and echocardiographic studies were unaware of the
reatment assigned to patients.
lasma NT-pro-BNP concentrations. The NT-pro-
NP plasma concentrations were determined by a commer-
ially available enzyme-linked immunosorbent assay (Roche
iagnostics, Mannheim, Germany). The average of tripli-
ate undiluted determinations was calculated.
tatistical analysis. Data are presented as mean values 
D. A two-way repeated measures analysis of variance with
Tukey post-hoc test was used. To determine differences in
hanges from baseline, and 6 and 12 months in hemody-
amics, NYHA FC and biochemical measurements analysis
f covariance (ANCOVA) adjusting for baseline data was
sed. The relationship between the final dose of carvedilol
chieved and changes in both functional and biochemical
arameters was determined using ANCOVA adjusting for
aseline values. An unpaired Student t test was used for
omparison of baseline data. Significance was assumed at a
wo-tailed probability value of 0.05.
ESULTS
aseline characteristics. Of the 100 patients screened, 22
ere not enrolled because they did not fulfill the inclusion or
xclusion criteria. Eleven patients died during the 12-month
tudy period (6 in the ACEI-first group), and 10 patients were
ot available for follow-up (5 in the ACEI-first group).
atients who did not complete the study were not included inhe final analysis of the data. There were no differences in
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November 2, 2004:1825–30 Sequence of Therapy in Heart Failureaseline hemodynamic, cardiac function, and biochemical
haracteristics between the groups (Table 1, Figs. 1 to 3).
here were no differences between the groups in age (ACEI-
rst group 51 11 years, BB-first group 48 10 years)
nd percentage of male patients (ACEI-first group  47%,
B-first group  44%). There were no differences in hemo-
igure 1. Impact of initiating carvedilol before perindopril therapy (beta-
locker [BB]-first group) compared with the effect of the commencement
f perindopril first (angiotensin-converting enzyme inhibitor [ACEI]-first
roup) on New York Heart Association functional class (NYHA FC). *p
able 1. Clinical Parameters and Left Ventricular Function at 0,
eceiving Either Perindopril (ACEI-First) or Carvedilol (BB-Fir
Initial Therapy ACEI-First BB-First A
Months of Treatment 0 0
Sample Number 30 27
P (mm Hg) 115  14/76  11 113  15/74  12 121 
eart rate
(beats/min1)
87  15 88 17
YHA FC (I/II/II/IV) 4/12/11/1 3/9/12/3 1
VEDD (mm) 65.5 7.9 65.3 6.8 62
VESD (mm) 56.6 7.8 57.6 7.8 53
eceleration time (ms) 154  93 133 45 1
/A 1.46 0.87 1.86 1.25 1.
p  0.05, †p  0.005 versus baseline data (Table 1); ‡p  0.05, §p  0.01 versus
ACEI  angiotensin-converting enzyme inhibitor; BB  beta-blocker; BP 
nd-diastolic diameter; LVESD  left ventricular end-systolic diameter; NYHA FCv
.05 versus baseline data (0 months); †p  0.05 versus absolute values and
hange from baseline in the ACEI-first group.ynamic, cardiac function, and biochemical or demographic
haracteristics between patients enrolled, completing 6 months
f the study, and completing 12 months of the study (data not
hown).
YHA FC, blood pressure, heart rate, and NT-pro-
NP. In patients in both study groups, there was an
mprovement in NYHA FC at 6 and 12 months (Fig. 1). In
oth groups most of the improvement occurred in the first
months with minimal additional changes noted between 6
nd 12 months (Fig. 1). However, improvement in NYHA
C was consistently greater in the BB-first group (Fig. 1).
ence, NYHA FC at 12 months was lower in the BB-first
roup (Fig. 1).
Systolic blood pressure was increased at six months in the
B-first group (Table 1), and this change was maintained
or the next six months (Table 1). In patients in whom
erindopril was initiated at baseline, no alteration in systolic
lood pressure was noted (Table 1).
In the BB-first group, a marked reduction in heart rate
as noted at both 6 and at 12 months (Table 1). In contrast,
n the ACEI-first group, a reduction in heart rate was noted
t 12 but not at 6 months (Table 1). A greater decrease in
eart rate at 6 but not at 12 months was noted in the
B-first group (Table 1).
V function and dimensions. There was an increase in
VEF determined using radionuclide techniques in the
B-first group after both 6 and 12 months (Fig. 2).
lthough there was an increase in LVEF after 12 months in
he ACEI-first group (Fig. 2), no significant change in
VEF was noted in the first six months of therapy (Fig. 2).
ence, improvement in LVEF in the BB-first group was
argely attributed to the effects of carvedilol. The increase in
VEF and the final LVEF was greater in the BB-first group
radionuclide: 15  16% vs. 6  13%, p  0.05) (Fig. 2).
imilar therapeutic trends were noted for LVEF determined
sing echocardiography (data not shown).
There was a decrease in left ventricular end-systolic
iameter (LVESD) after both 6 and 12 months (Table 1) in
he BB-first group. In addition there was a decrease in left
d 12 Months of Therapy in Patients With Heart Failure
oup) as Initial Therapy
First BB-First ACEI-First BB-First
6 12 12
27 30 27
74  16 124  20*/79  15 119  17/73  12 122  19*/75  14
16 76 18*‡ 76  17* 73 15†
7/1 13/7/7/0 11/10/9/0 22/3/2/0
7.1 62.0  8.0 62.6  7.9 60.0 11.6†
8.2 51.6  10.4† 53.0 8.9 48.5 12.4†
58 207 73† 167  60 204 55†§
0.60 1.27  0.73 1.56 0.79 1.17 0.63*‡
e from baseline in the ACEI- first group (analysis of covariance).
pressure; E/A  ratio of E wave to A wave velocity; LVEDD  left ventricular
ew York Heart Association functional class.6, an
st Gr
CEI-
6
30
22/
85
1/11/
.4
.2
55
34
changentricular end-diastolic diameter (LVEDD) after 12
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Sequence of Therapy in Heart Failure November 2, 2004:1825–30onths with a trend for a decrease after 6 months (Table 1)
n the BB-first group. In the ACEI-first group, a trend for
reduction in LVESD and LVEDD occurred at both 6 and
t 12 months (Table 1), but these changes failed to reach
ignificance.
In the BB-first group, there was a marked prolongation of
he deceleration time at both 6 and at 12 months (Table 1)
ith no significant changes in the ACEI-first group.
lasma NT-pro BNP concentrations. In both groups of
atients, plasma NT-pro-BNP concentrations were markedly
aised compared with normal values for healthy, age-matched
olunteers from the same population (BB-first group: 219 
41 pg/ml; ACEI-first group: 222  254 pg/ml; normal
olunteers: 12 pg/ml, p  0.0001). The BB-first group had a
arked reduction in plasma NT-pro BNP concentrations at
igure 2. Impact of initiating carvedilol before perindopril therapy (beta-
locker [BB]-first group) compared with the effect of the commencement
f perindopril first (angiotensin-converting enzyme inhibitor [ACEI]-first
roup) on left ventricular ejection fraction (EF), determined using radio-
uclide techniques. *p 0.05; **p 0.001 versus baseline data (0 months);
p  0.05 versus absolute values and change from baseline in the
CEI-first group. Muga  multiple gated equilibrium cardiac blood pool
cintigraphic technique.oth 6 and 12 months (Fig. 3). In the ACEI-first group, a brend for a reduction in plasma NT-pro-BNP concentrations
ccurred at 12 months but not at 6 months of therapy (Fig. 3).
he decrease in plasma NT-pro-BNP concentrations was,
herefore, greater, and final plasma NT-pro-BNP concentra-
ions at 12 months were lower in the BB-first group (166 
42 pg/ml vs. 51  384 pg/ml) (Fig. 3).
ose of medication and relationship with functional
hanges. All patients received digoxin at a dose of 0.25 mg
aily throughout the study. The mean dose of furosemide
as lower in the BB-first group (Table 2). Patients in the
B-first tolerated a higher dose of carvedilol at 12 months
ompared with patients in the ACEI-first group (Table 2).
n the ACEI-first group, 13 patients only could tolerate
2.5 mg carvedilol daily, and 3 patients 25 mg carvedilol
aily, whereas the rest could tolerate 50 mg daily. In
ontrast, in the BB-first group, all except two patients (who
olerated a 25-mg dose) could tolerate a 50-mg dose.
aximal tolerable doses of carvedilol were achieved within
wo months of initiating therapy in both groups. Lower
oses of carvedilol were achieved in the ACEI-first group
ecause of complaints of intolerable dizziness at higher
oses. No differences in the dose of perindopril were
chieved in the two groups (Table 2). An association
igure 3. Impact of initiating carvedilol before perindopril therapy (beta-
locker [BB]-first group) compared with the effect of the commencement
f perindopril first (angiotensin-converting enzyme inhibitor [ACEI]-first
roup) on plasma N-terminal-pro-brain natriuretic peptide (NT-pro-
NP) concentrations. *p  0.0005 versus baseline data (0 months); †p 
.01 versus absolute values and change from baseline in the ACEI-first
roup.etween the final dose of carvedilol achieved and changes in
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November 2, 2004:1825–30 Sequence of Therapy in Heart FailureVEF (radionuclide values, p  0.02; echocardiographic
alues, p  0.01), NYHA FC (p  0.0001), and decelera-
ion time (p  0.05) from baseline to 12 months was noted.
ISCUSSION
n the present study, we have shown that, in patients with
ewly diagnosed congestive cardiac failure, initiation of
reatment with carvedilol before, as compared with subse-
uent to, an ACEI results in greater improvements in LV
unction and symptoms. Patients receiving carvedilol at the
utset tolerated a higher dose of carvedilol and required
ower doses of diuretic agents at 12 months after initiating
herapy. In the group receiving carvedilol first (BB-first
roup), better improvements in functional class, more
arked changes in LV systolic (LVEF) and diastolic func-
ion, and a biochemical index of raised filling pressures
plasma NT-pro-BNP concentrations) were noted.
Although blockers of neurohumoral activation have
roven benefits on hemodynamic function and symptoms in
eart failure (14–16), the present study is the first to
emonstrate that the order of initiation of these agents
nfluences improvements in NYHA FC and both systolic
nd diastolic function in patients with heart failure and
ump dysfunction. Patients who received carvedilol as initial
herapy tolerated a higher dose of carvedilol after one year of
herapy. The higher dose of the beta-adrenoreceptor blocker
chieved in the group receiving carvedilol first could, in part,
xplain the differences in hemodynamic and symptomatic
mprovement between the two groups. Indeed, in the
resent study, the final dose of carvedilol achieved was
ssociated with improvements in LVEF, diastolic function,
nd NYHA FC. This is consistent with data that demon-
trates a better outcome after the use of higher doses of both
CEI and beta-adrenoreceptor blockers in heart failure
17,18).
An alternative explanation for the differences in hemo-
ynamic and symptomatic outcomes between the groups in
he present study is that beta-adrenoreceptor blocker ther-
py is more effective than ACEI therapy in newly diagnosed
eart failure. Sympathetic activation occurs before that of
he renin-angiotensin-aldosterone system in heart failure, as
hown by measurements of plasma neurohormonal levels in
he Studies Of Left Ventricular Dysfunction (SOLVD)
able 2. Doses of Pharmacologic Agents Received After 12
onths of Therapy in Patients With Heart Failure in Whom
ither Perindopril (ACEI-First) or Carvedilol (BB-First)
herapy Was Initiated First
ACEI-First
Group
BB-First
Group
urosemide (mg) 116  44 80  37*
arvedilol (mg) 33 18 43  17*
erindopril (mg) 7.3  2.1 7.2  1.6
p  0.05 versus the other group.
Abbreviations as in Table 1.rials (8). Thus, prevention of the deleterious effects of aeta-adrenergic stimulation should be achieved as early as
ossible if LV dysfunction is present (19). Evidence to
upport this hypothesis is that marked differences in changes
n measures of LV systolic function and functional class
etween the two groups were noted after six months of
herapy.
In the treatment of heart failure, reverse remodeling is
egarded as one of the more important determinants of
ong-term outcome. Although ACEI arrest the remodeling
rocess, no reverse remodeling has been observed with this
lass of agents (14). In contrast, carvedilol administered to
atients with heart failure due to ischemic heart disease
everses LV remodeling (20). In this regard, in the present
tudy, LV diastolic cavity dimensions were reduced in the
roup of patients in whom carvedilol was initiated first,
hereas in those patients receiving the ACEI as initial
herapy only a trend for a reduction was noted.
Patients included in the present study had newly diag-
osed heart failure due to idiopathic dilated cardiomyopa-
hy. Although temporal changes in the cellular, molecular,
iochemical, and interstitial changes that characterize heart
ailure have been poorly studied in idiopathic dilated car-
iomyopathy, an agent with the capacity to modulate these
lterations, such as carvedilol (21,22), might be the drug of
hoice to initiate in order to appropriately reverse the
emodeling process.
In the present study, plasma concentrations of NT-pro-
NP were markedly reduced in patients receiving carvedilol
ompared with perindopril as initial therapy. B-type natri-
retic peptide, a cardiac neurohormone synthesized pre-
ominantly in the LV of the heart, appears to be a powerful
redictor of prognosis in heart failure (23) and has been
sed to monitor therapy (11). It is, therefore, of potential
rognostic importance that patients in the present study
eceiving carvedilol as initial therapy achieved a more
ubstantial decrease in plasma NT-pro-BNP concentrations
ompared with those receiving an ACEI first. As BNP has
een suggested to be a marker for cardiac remodeling (24),
otential mechanisms for its decline in our study could
nclude reverse remodeling in addition to a reduction in
entricular filling and myocardial stretch.
The limitations of the present study include the lack of
ortality data, an outcome that cannot be adequately
ssessed in a single-center study. In addition, this was an
pen-label rather than double-blind study. Nevertheless, in
he present study, assessments of hemodynamic function
ere conducted by investigators and laboratory technicians
naware of medication received by patients. Lastly, with the
esign of this study, we were not able to determine whether
he benefit seen in the group of patients receiving carvedilol
s initial therapy was truly due to the timing of carvedilol
dministration or rather whether we achieved a carvedilol
ose threshold beyond which reverse remodeling occurs.
In conclusion, the present study provides the first evi-
ence to indicate that, in comparison with the conventional
pproach to treating heart failure, where BBs are added to
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Sequence of Therapy in Heart Failure November 2, 2004:1825–30CEI therapy, initiation of carvedilol therapy before an
CEI leads to higher tolerable doses of carvedilol, better
mprovements in NYHA FC, and more marked changes in
V systolic and diastolic function in patients with newly
iagnosed heart failure. These results are encouraging and
uggest an alternative therapeutic approach in patients with
ewly diagnosed heart failure, data that requires confirma-
ion in larger trials with mortality as one of the outcome
easures.
eprint requests and correspondence: Prof. Karen Sliwa, De-
artment of Cardiology, Chris-Hani Baragwanath Hospital, P.O.
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